Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xiaoming Cui

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Journal of Medicinal Chemistry|April 28, 2026
DMPK Considerations for the Development of Covalent Drugs: Insights from an IQ AssessmentJulian Dopstadt, Kamelia Behnia, Xiaoming Cui, et al.
European Journal of Cancer (Oxford, England : 1990)|July 10, 2024
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancerEnriqueta Felip, Giulio Metro, Ross A Soo, et al.
International Journal of Molecular Sciences|August 12, 2022
MATE1 Deficiency Exacerbates Dofetilide-Induced ProarrhythmiaMuhammad Erfan Uddin, Eric D Eisenmann, Yang Li, et al.
The New England Journal of Medicine|September 3, 2020
Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung CancerJürgen Wolf, Takashi Seto, Ji-Youn Han, et al.
Cancer Discovery|April 11, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Journal of Medicinal Chemistry|June 8, 2013
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trialsThomas H Marsilje, Wei Pei, Bei Chen, et al.
Journal of Medicinal Chemistry|September 29, 2006
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infectionSrikanth Venkatraman, Stéphane L Bogen, Ashok Arasappan, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Journal of Medicinal Chemistry|April 28, 2026
DMPK Considerations for the Development of Covalent Drugs: Insights from an IQ AssessmentJulian Dopstadt, Kamelia Behnia, Xiaoming Cui, et al.
European Journal of Cancer (Oxford, England : 1990)|July 10, 2024
Capmatinib plus nazartinib in patients with EGFR-mutated non-small cell lung cancerEnriqueta Felip, Giulio Metro, Ross A Soo, et al.
International Journal of Molecular Sciences|August 12, 2022
MATE1 Deficiency Exacerbates Dofetilide-Induced ProarrhythmiaMuhammad Erfan Uddin, Eric D Eisenmann, Yang Li, et al.
The New England Journal of Medicine|September 3, 2020
Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung CancerJürgen Wolf, Takashi Seto, Ji-Youn Han, et al.
Cancer Discovery|April 11, 2022
Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12CAndreas Weiss, Edwige Lorthiois, Louise Barys, et al.
Journal of Medicinal Chemistry|June 8, 2013
Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trialsThomas H Marsilje, Wei Pei, Bei Chen, et al.
Journal of Medicinal Chemistry|September 29, 2006
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infectionSrikanth Venkatraman, Stéphane L Bogen, Ashok Arasappan, et al.
Pageof 7